0001179110-13-011531.txt : 20130703 0001179110-13-011531.hdr.sgml : 20130703 20130703165947 ACCESSION NUMBER: 0001179110-13-011531 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130701 FILED AS OF DATE: 20130703 DATE AS OF CHANGE: 20130703 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SYNTA PHARMACEUTICALS CORP CENTRAL INDEX KEY: 0001157601 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 45 HARTWELL AVE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-274-8200 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gollust Keith R CENTRAL INDEX KEY: 0001325712 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33277 FILM NUMBER: 13953841 MAIL ADDRESS: STREET 1: C/O SYNTA PHARMACEUTICALS CORP. STREET 2: 45 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 edgar.xml FORM 4 - X0306 4 2013-07-01 0 0001157601 SYNTA PHARMACEUTICALS CORP SNTA 0001325712 Gollust Keith R C/O SYNTA PHARMACEUTICALS CORP. 45 HARTWELL AVENUE LEXINGTON MA 02421 1 0 0 0 Common Stock 2013-07-01 4 A 0 8000 0 A 324255 D Common Stock 2013-07-01 4 A 0 4000 0 A 328255 D Common Stock 2013-07-01 4 A 0 2000 0 A 330255 D Common Stock 2013-07-01 4 A 0 1000 0 A 331255 D Common Stock 2013-07-01 4 A 0 1000 0 A 332255 D Common Stock 2673383 I By Wyandanch Partners, L.P. Common Stock 175000 I By Keith R. Gollust Roth IRA Director Stock Option (Right to Buy) 5.00 2013-07-01 4 A 0 10000 0 A 2023-07-01 Common Stock 10000 10000 D Director Stock Option (Right to Buy) 5.00 2013-07-01 4 A 0 4500 0 A 2023-07-01 Common Stock 4500 4500 D Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2013, December 31, 2013, March 31, 2014 and June 30, 2014, provided the Reporting Person continues to serve as a director of the Issuer on such date. Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2013, December 31, 2013, March 31, 2014 and June 30, 2014, provided the Reporting Person continues to serve as Chairman of the Board of Directors of the Issuer on such date. Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2013, December 31, 2013, March 31, 2014 and June 30, 2014, provided the Reporting Person continues to serve as Chairman of the Nominating and Governance Committee of the Board of Directors of the Issuer on such date. Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2013, December 31, 2013, March 31, 2014 and June 30, 2014, provided the Reporting Person continues to serve as a member of the Audit Committee of the Board of Directors of the Issuer on such date. Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2013, December 31, 2013, March 31, 2014 and June 30, 2014, provided the Reporting Person continues to serve as a member of the Compensation Committee of the Board of Directors of the Issuer on such date. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. The option vests as to 25% of the shares on each of September 30, 2013, December 31, 2013, March 31, 2014 and June 30, 2014, provided the Reporting Person continues to serve as a director of the Issuer on such date. The option vests as to 25% of the shares on each of September 30, 2013, December 31, 2013, March 31, 2014 and June 30, 2014, provided the Reporting Person continues to serve as Chairman of the Board of Directors of the Issuer on such date. /s/ Brian Keane, Attorney-in-Fact 2013-07-03